Influence of the PPAR gamma -agonist Pioglitazone on endothelial function in the peripheral and myocardial vascular territories and on myocardial efficiency in obese subjects - Pioglitazone

Department of Nuclear Medicine0 个研究点目标入组 62 人开始时间: 2005年4月5日最近更新: 2016年11月7日

适应症

试验速览

暂无简介。

•Nondiabetic obese subjects between 20 to 50 years of age (BMI > 30 kg/m² in men or > 25 kg/m² in women; waist circumference >102 cm in men and > 88cm in women, n=44) with insulin resistance as suggested by an impaired fasting glucose concentration (>110 mg/dl), elevated triglyzerides (>130 mg/dl), a triglyzeride to HDL ratio > 3.0 and an insulin concentration above 109 pmol/l (> 15 µU/ml) will be included in the study
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•Exclusion criteria will be coronary artery disease and any major medical illness including uncontrolled or malignant hypertension. Study participants should not take any medication known to influence insulin resistance or lipid metabolism and should be nonsmokers.
•Controls will be healthy age matched subjects.
•Also pregnant and nursing women are excluded from the trial.

发起方